Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells

Human Pathology

Volumn 41, Issue 6, 2010, Pages 848-858

  Fakhry, Hussein ^a   Miyamoto, Tsutomu ^b   Kashima, Hiroyasu ^b   Suzuki, Akihisa ^b   Ke, He ^c   Konishi, Ikuo ^d   Shiozawa, Tanri ^b  

^a ASSIUT UNIVERSITY   (Egypt)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SUN YAT SEN UNIVERSITY   (China)

^d KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Endometrial carcinoma; HDAC; Immunohistochemistry; Prognosis

Indexed keywords

APICIDIN; CYCLIN A; CYCLIN D1; CYCLIN E; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P21; PROTEIN P27; TRICHOSTATIN A;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; GENE REPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PROGNOSIS;

ADULT; AGED; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HUMANS; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; PEPTIDES, CYCLIC; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 77951976758     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.11.012     Document Type: Article

References (36)

1. Ronnett B., Zaino R., Ellenson L., and Kurman R. Endometrial carcinoma. Blaustein's pathology of the female genital tract. 5th ed (2002), Springer-Verlag, New York 501-559
2. Sorosky J.I. Endometrial cancer. Obstet Gynecol 111 (2008) 436-447
3. Creasman W.T., Odicino F., Maisonneuve P., et al. Carcinoma of the corpus uteri. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95 Suppl 1 (2006) S105-S143
4. Ueda S.M., Kapp D.S., Cheung M.K., et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 198 (2008) 218.e1-218.e6
5. Li S.F., Shiozawa T., Nakayama K., Nikaido T., and Fujii S. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma. Cancer 77 (1996) 321-329
6. Shih H.C., Shiozawa T., Kato K., et al. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol 34 (2003) 471-478
7. Weichert W., Roske A., Gekeler V., et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98 (2008) 604-610
8. Weichert W., Roske A., Gekeler V., et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncology 9 (2008) 139-148
9. Krusche C.A., Vloet A.J., Classen-Linke I., et al. Histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas. Hum Reprod 22 (2007) 2956-2966
10. Fritzsche F.R., Weichert W., Roske A., et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8 (2008) 381
11. Felsenfeld G. Chromatin as an essential part of the transcriptional mechanism. Nature 355 (1992) 219-224
12. Strahl B.D., and Allis C.D. The language of covalent histone modifications. Nature 403 (2000) 41-45
13. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97 (2000) 10014-10019
14. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 9 (1999) 40-48
15. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6 (2006) 38-51
16. Weichert W., Denkert C., Noske A., et al. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 10 (2008) 1021-1027
17. Takai N., Desmond J.C., Kumagai T., et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10 (2004) 1141-1149
18. Jiang S., Dowdy S.C., Meng X.W., et al. Histone deacetylase inhibitors induce apoptosis in both type I and type II endometrial cancer cells. Gynecol Oncol 105 (2007) 493-500
19. Ahn M.Y., Lee J., Na Y.J., et al. Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells. Chem Biol Interact 179 (2009) 169-177
20. Ueda T., Takai N., Nishida M., Nasu K., and Narahara H. Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells. Int J Mol Med 19 (2007) 301-308
21. Shiozawa T., Miyamoto T., Kashima H., Nakayama K., Nikaido T., and Konishi I. Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence. Oncogene 23 (2004) 8603-8610
22. Nagy L., Kao H.Y., Chakravarti D., et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89 (1997) 373-380
23. Shiozawa T., Shih H.C., Miyamoto T., et al. Cyclic changes in the expression of steroid receptor coactivators and corepressors in the normal human endometrium. J Clin Endocrinol Metab 88 (2003) 871-878
24. Sakai N., Maruyama T., Sakurai R., et al. Involvement of histone acetylation in ovarian steroid-induced decidualization of human endometrial stromal cells. J Biol Chem 278 (2003) 16675-16682
25. Uchida H., Maruyama T., Nagashima T., Asada H., and Yoshimura Y. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology 146 (2005) 5365-5373
26. Weichert W., Roske A., Niesporek S., et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 14 (2008) 1669-1677
27. David G., Alland L., Hong S.H., Wong C.W., DePinho R.A., and Dejean A. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 16 (1998) 2549-2556
28. Inokoshi J., Katagiri M., Arima S., et al. Neuronal differentiation of neuro 2a cells by inhibitors of cell cycle progression, trichostatin A and butyrolactone I. Biochem Biophys Res Commun 256 (1999) 372-376
29. Margueron R., Licznar A., Lazennec G., Vignon F., and Cavailles V. Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells. J Endocrinol 179 (2003) 41-53
30. Han J.W., Ahn S.H., Park S.H., et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 60 (2000) 6068-6074
31. Cheong J.W., Chong S.Y., Kim J.Y., et al. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells. Clin Cancer Res 9 (2003) 5018-5027
32. Jones P., Altamura S., De Francesco R., et al. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. J Med Chem 51 (2008) 2350-2353
33. Avila A.M., Burnett B.G., Taye A.A., et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 117 (2007) 659-671
34. Roh M.S., Kim C.W., Park B.S., et al. Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells. Apoptosis 9 (2004) 583-589
35. Woo H.J., Lee S.J., Choi B.T., Park Y.M., and Choi Y.H. Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells. Exp Mol Pathol 82 (2007) 77-84
36. Alao J.P., Stavropoulou A.V., Lam E.W., and Coombes R.C. Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells. Mol Cancer 5 (2006) 40